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Abstract
Background: Accurate assessment of a patient’s risk of recurrence and treatment response is an important prerequisite of
personalized therapy in lung cancer. This study extends a previously described non-small cell lung cancer prognostic model
by the addition of chemotherapy and co-morbidities through the use of linked SEER-Medicare data.
Methodology/Principal Findings: Data on 34,203 lung adenocarcinoma and 26,967 squamous cell lung carcinoma patients
were used to determine the contribution of Chronic Obstructive Pulmonary Disease (COPD) to prognostication in 30
treatment combinations. A Cox model including COPD was estimated on 1,000 bootstrap samples, with the resulting model
assessed on ROC, Brier Score, Harrell’s C, and Nagelkerke’s R2 metrics in order to evaluate improvements in prognostication
over a model without COPD. The addition of COPD to the model incorporating cancer stage, age, gender, race, and tumor
grade was shown to improve prognostication in multiple patient groups. For lung adenocarcinoma patients, there was an
improvement on the prognostication in the overall patient population and in patients without receiving chemotherapy,
including those receiving surgery only. For squamous cell carcinoma, an improvement on prognostication was seen in both
the overall patient population and in patients receiving multiple types of chemotherapy. COPD condition was able to
stratify patients receiving the same treatments into significantly (log-rank p,0.05) different prognostic groups, independent
of cancer stage.
Conclusion/Significance: Combining patient information on COPD, cancer stage, age, gender, race, and tumor grade could
improve prognostication and prediction of treatment response in individual non-small cell lung cancer patients. This model
enables refined prognosis and estimation of clinical outcome of comprehensive treatment regimens, providing a useful tool
for personalized clinical decision-making.
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Introduction
Lung cancer is the leading cause of cancer-related deaths in
industrialized countries [1]. Non-small cell lung cancer (NSCLC)
accounts for about 80% of lung cancer cases. Major histology of
NSCLC includes lung adenocarcinoma and squamous cell lung
carcinoma. Tumor recurrence and metastasis is the major
treatment failure (i.e., death) of lung cancer. In the current
practice, surgical resection is the major treatment option for stage I
NSCLC patients. Nevertheless, up to 50% of stage I NSCLC
patients will develop and die from tumor recurrence within five
years following the surgery [2,3]. It is therefore important to select
early stage NSCLC patients for more aggressive treatment. On the
other hand, patients with positive lymph node involvements are
recommended to receive adjuvant chemotherapy. However, the
benefits of chemotherapy on NSCLC are not convincing [4].
Recent meta-analysis of 12 randomized trials showed that the use
of combination chemotherapy had significantly better clinical
outcome than single agent chemotherapy [5]. Currently, a clinical
decision scheme is needed to recommend which chemotherapy
and treatment course would be optimal for a particular patient.
One of the most important factors influencing the survival of
patients with lung and bronchus cancers is the selection of an
appropriate course of therapy based on an accurate assessment of
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patient risk. However, the selection of a course of therapy is
currently based largely on cancer stage alone despite the
contribution of other factors to patient survival. In particular,
comorbidities such as COPD can have a significant effect on long-
term survival due to varying treatment candidacy, increased
complication rate, or decreased treatment efficacy [6–8], and the
prevalence of COPD is elevated in lung cancer patients
independent of age, gender, and smoking history [9]. A major
impediment is determining the contribution of each of these
factors, including COPD, cancer stage, tumor grade, age, gender,
race and histology, in a comprehensive prognostic model. It would
be clinically useful to develop such a model to assess individual
patient treatment outcome in comprehensive therapeutic regi-
mens, including surgery, radiation, and multiple chemotherapeutic
agents, by using large-scale patient medical records.
Comorbidities which affect lung function, such as COPD, are
likely to influence post-operative survival independent of their
effects on surgical candidacy due to the possibility of decreased
lung function. The Forced Expiratory Volume in 1 second (FEV1)
of a patient, a potential indicator of COPD, was found to be a
significant prognostic factor in a model controlling for other
clinical variables such as nodal status [10,11]. Although COPD
and lung cancer are often seen together in patients due to their
shared association with smoking behavior, neither condition is a
clinical end-point for the other. Therefore, it is important to
investigate whether COPD is a potential prognostic factor of lung
cancer and how to incorporate it in the treatment selection.
Previously, we developed a prognostic model utilizing similar
data derived from the Surveillance Epidemiology and End-Results
(SEER) cancer registry initiative [12]. The previous approach
utilized clinical, pathological, and demographic variables in a
single model to achieve superior prognostication over a similar
model using cancer stage alone. This model was however limited
by the data in that the use of specific chemotherapies and the
presence of comorbidities could not be determined. This study
extends the previous analysis by utilizing patient medical records
from the linked SEER-Medicare database. These additional data
allow for the role of COPD in prognostication to be determined
across combinations of surgical, radiological, and chemothera-
peutic treatments [13–15]. In this study, we sought to 1) develop a
comprehensive lung cancer prognostic model by incorporating
information of COPD, age, gender, race, tumor grade, cancer
stage, AJCC staging edition, and histology; 2) estimate 2-year and
5-year survival probability of patients receiving surgery, radiation,
and chemotherapy, including Platinum-based, Platinum/Taxane,
and Carboplatin/Paclitaxel/Avastin; 3) develop an online NSCLC
prognostic tool for individualized clinical decision-making.
Patients and Methods
Patient data was obtained from the linked SEER-Medicare
database, a combination of population-based registry data and
billing histories for patients covered by Medicare [16]. In short,
data from participating SEER registries were linked with Medicare
data through the use of social security number, census tract, age,
and other identifying variables [15]. The resulting data contain
information on treatments administered, co-morbidities present in
the patient, clinical presentation, survival, and demographics.
Criteria for inclusion in this analysis were a diagnosis of lung or
bronchus cancer between 1991 and 2005, and complete informa-
tion on age, race, gender, tumor grade and stage, as well as valid
Table 1. Distribution of demographic and clinical characteristics of patients diagnosed with adenocarcinoma or squamous cell
carcinoma in the original AJCC 3rd and 6th staging editions and recoded 7th edition.
Patient Information Adenocarcinoma Squamous Cell Carcinoma
AJCC 3rd AJCC 6th AJCC 7th AJCC 3rd AJCC 6th AJCC 7th
Stage
1 9,510 (35.6%) 3,127 (42%) 2,371 (33.3%) 7,110 (33%) 1,968 (36.5%) 1,466 (28.6%)
2 1,475 (5.5%) 580 (7.8%) 1,400 (19.7%) 1,272 (5.9%) 574 (10.6%) 958 (18.7%)
3a 2,610 (9.8%) 661 (8.9%) 1,145 (16.1%) 3,074 (14.2%) 650 (12%) 1,114 (21.7%)
3b 4,638 (17.3%) 919 (12.3%) 438 (6.2%) 4,928 (22.8%) 907 (16.8%) 496 (9.7%)
4 8,516 (31.8%) 2,167 (29.1%) 1,762 (24.8%) 5,188 (24.0%) 1296 (24%) 1,089 (21.3%)
Grade
1 3,436 (12.8%) 1,189 (16%) 1,143 (16%) 1,000 (4.6%) 191 (3.5%) 180 (3.5%)
2 8,780 (32.8%) 2,892 (38.8%) 2,800 (39.3%) 8,384 (38.9%) 2,284 (42.3%) 2,182 (42.6%)
3 13,885 (51.9%) 3,235 (43.4%) 3,044 (42.8%) 11,713 (54.3%) 2,850 (52.8%) 2,694 (52.6%)
4 648 (2.4%) 138 (1.9%) 129 (1.8%) 475 (2.2%) 70 (1.3%) 67 (1.3%)
Age, Mean(SD) 73.4 (7.2) 74.0 (7.6) 73.9 (7.6) 73.5 (6.9) 74.1 (7.4) 74.2 (7.3)
Race
White 23,218 (86.8%) 6,515 (87.4%) 6,219 (87.4%) 18,456 (85.6%) 4,727 (87.6%) 4,490 (87.6%)
Black 1,945 (7.3%) 531 (7.1%) 508 (7.1%) 2,232 (10.3%) 486 (9%) 459 (9.0%)
Asian/Pac. Islander 1,586 (5.9%) 408 (5.5%) 389 (5.5%) 884 (4.1%) 182 (3.4%) 174 (3.4%)
Sex
Male 13,678 (51.1%) 3,556 (47.7%) 3,372 (47.4%) 14,111 (65.4%) 3,370 (62.5%) 3,186 (62.3%)
Female 13,071 (48.9%) 3,898 (52.3%) 3,744 (52.6%) 7,461 (34.6%) 2,025 (37.5%) 1,937 (37.7%)
+COPD Diagnosis 7,948 (29.7%) 2,647 (35.5%) 2,538 (35.7%) 8,521 (39.5%) 2,568 (47.6%) 2,431 (47.6%)
doi:10.1371/journal.pone.0100994.t001
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follow-up and billing history. This set of patients was further
refined to only include those with tumors broadly classifiable as
either squamous cell carcinoma or adenocarcinoma. Cases
reported solely from autopsy or death certificate were excluded.
In total, 34,203 patients with lung adenocarcinomas and 26,967
patients with squamous cell lung carcinomas met these criteria
(Table 1).
The administration of chemotherapy was determined using
Healthcare Common Procedure Coding System (HCPCS) codes
in combination with International Classification of Diseases (ICD)
codes. For each patient, all records were searched for entries with
an HCPCS code indicating that chemotherapy was administered.
These entries were then cross referenced with the ICD primary
and secondary diagnosis codes for that entry to ensure that the
agent was being administered for the treatment of lung or
bronchus cancers. Four specific agents, cisplatin, carboplatin,
docetaxel, and paclitaxel were considered in addition to a broad
group covering a variety of chemotherapeutic agents.
Patients were also analyzed according to variable administration
of curative surgery and radiological treatment. Five groups were
formed on the basis of surgical and radiological treatments; a
group containing all patients regardless of treatment, a group for
patients having surgery without radiation, another for those having
radiation without surgery, a group with both surgery and
radiation, a group of patients without any treatment listed.
Surgical and radiological treatment group assignments were based
on the presence of any curative treatment of that type in the SEER
portion of the data.
Comorbidities were measured as components of a version of the
Charlson Comorbidity Index (CCI) adapted for use with
administrative data [17–19]. Comorbidities were determined
using code available from the NCI designed specifically for this
SEER-Medicare dataset (http://healthservices.cancer.gov/
seermedicare/program/comorbidity.html), under the assumption
that the presence of a treatment for a specific disease in the billing
history was indicative of its presence in the patient at the time. All
claims out to three years prior to the diagnosis with lung cancer
were analyzed for specific sets of ICD-9 codes indicative of one of
the conditions listed in the CCI. Upon finding a relevant ICD
code for any of the 18 conditions included in the index, patients
were flagged as being positive for the corresponding condition.
The determination of chemotherapy use and co-morbidities was
done using SAS version 9.2 in the PC environment.
Patient age, race, and gender were identified using information
in the SEER portion of the data, with Black and Asian/Pacific
Islander patients being compared to Whites as a reference group.
Tumor grade was also identified from the SEER portion of the
data. Tumor grades 1 and 2 were grouped together and served as
a reference group for grades 3 and 4, which were also grouped in
the Cox models. Cancer stage was listed in the SEER portion of
the data in either the 3rd or 6th Edition of the AJCC staging
system. Records coded using the 6th Edition were able to be
recoded to the 7th Edition provided that they had complete and
valid information on tumor size, extension, nodal involvement,
and distant metastases. Cancer stage I was used as a reference
group in the Cox models. The number and distribution of patient
characteristics is detailed in Table 1.
Cox modeling was used to estimate a proportional hazards
model for use in quantitatively assessing patient risk given multiple
variables. Two separate models were estimated: a Full model
containing information on patient age, race, gender, histology,
tumor grade and cancer stage as developed in our previous study
[12], and a COPD model containing the same variables with an
additional indicator of the presence of COPD. The performance
of these two models was compared to evaluate whether the
addition of COPD could improve prognostication and prediction
of treatment outcome. For both the Full and COPD models, a
total of 1,000 Cox proportional-hazard models were estimated
using bootstrapped samples equal in size to the original patient
cohort. The distributions of coefficients were assessed for
normality, and the mean of each coefficient was taken. This set
of coefficients formed the final model for each approach.
The models were then assessed on a total of four metrics; area
under an ROC curve, Brier Score, Harrell’s c, and Nagelkerke’s
R2. The ROC measure represents the area under an integrated
ROC curve out to 60 months for the original 3rd Edition AJCC
staging, and 24 months for the 6th and recoded 7th Edition AJCC
staging. The Harrell’s c measure is similar to the ROC measure,
but takes into account the aspect of time. Nagelkerke’s R2 is a
generalized form of the coefficient of determination (R2) suitable
for survival models. The ROC, c-statistic, and R2 measures all
range from 0 to 1, with higher scores indicating better
performance. The Brier score is a measure of the accuracy of
survival predictions, and ranges from 0 to 1 with lower scores
being better. Similar to the ROC measure, the Brier score was
calculated at 36 months for the original AJCC staging and 24
months for the recoded AJCC staging. These estimations were
performed on 1,000 bootstrapped patient cohorts with a two-tailed
t-test being used to assess significant differences between models on
each test [20]. All model estimations and assessments were
performed using R version x64 2.15.0, with the survival, risksetAUC,
Design, rms, pec, and Hmisc packages.
The final models to be used in the online tool were constructed
using the coefficients estimated earlier for the models containing
cancer stage, tumor grade, histology, age, race/ethnicity, gender,
and COPD status. A total of 6 models, one for each AJCC Staging
Edition and histology combination, were constructed. Cutoffs for
each AJCC Edition and histology group were determined by
selecting a cutoff to partition patients into high- or low-risk groups
across the range of Hazard Scores in the total patient population
and testing the difference in survival between the Full and Stage
Only models, respectively, in an iterative manner. The final cutoffs
represent points at which the Full model shows the greatest
improvement in selecting both high- and low-risk patients in that
group. This stratification is represented in Figure S7. The final
coefficients and graphical representation of long-term survival as
determined by Hazard Score are shown for each model in the
results section. To estimate prognosis and treatment response of a
new patient, the Hazard Score is estimated using the coefficients
for each variable in the corresponding model. A representative
image of the web-based application (www.personalizedRx.org) of
the final prognostic model is provided in the results.
Results
Impact of COPD and other co-morbidities on NSCLC
survival
In patients receiving only surgery without radiation or
chemotherapy, COPD showed significant association (p,0.05;
Cox model) with lung cancer disease-specific survival (Table 2).
Other co-morbid conditions, including congestive heart failure,
peripheral vascular disease, cerebrovascular disease, diabetes with
sequelae, and gastrointestinal ulcers, also had a significant (p,
0.05; Cox model) association with disease-specific survival
(Table 2). As an independent prognostic factor, COPD status
alone was able to significantly stratify patients into high- and low-
risk groups (p,0.05) in all lung adenocarcinoma patients and
squamous cell lung carcinoma patients diagnosed with the AJCC
Predicting NSCLC Treatment Response
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3rd edition (Figure 1). In the significant cases, NSCLC patients
without COPD showed consistently and significantly better
survival when compared to those with COPD across the entire
period of post-operative follow-up, indicating that the effects of
COPD are manifested in both long- and short-term disease-
specific survival (Figure 1). Small sample size in the newer
squamous cell carcinoma groups diagnosed with the AJCC 6th
Edition and those recoded to the 7th Edition of AJCC staging
system may have impeded achieving a statistically significant
stratification by COPD. Still, the results indicate COPD patients
having shorter disease-specific survival.
COPD was further established as an independent prognostic
factor in the evaluation of stage 1, stage 2 and 3a patient groups
receiving specific treatments. Particularly, in stage 1 lung
adenocarcinoma and squamous cell lung carcinoma patients
receiving surgery without any systemic therapy, those without
COPD had significantly (p,0.05) better post-surgical survival than
those had COPD (Figures S1 to S4). Similar results were observed
in stage 2 and 3a NSCLC patients receiving surgery without
systemic therapy (Figures S1 to S6). More favorable clinical
outcome was also observed in stage 1, stage 2 and 3a patients
without COPD compared with those with COPD, who received
surgery or radiation with systemic therapy (Figures S1 to S6).
These results indicate that COPD is a significant and independent
prognostic factor of NSCLC.
Evaluation of Clinical, Pathological and Demographic
Factors in NSCLC prognosis
In order to assess which factors are important determinants in
NSCLC prognosis, patient clinical, pathological, and demographic
variables were compared in good prognosis (those who survived
more than 5 years after diagnosis) and poor prognosis (those who
died within 2 years after diagnosis) groups. To reduce the
confounding factor of treatment effects on clinical outcome, only
patients receiving surgery without radiation or chemotherapy were
included in this analysis. The results on patients diagnosed with
AJCC 3rd staging system were shown in Table 3. Detailed results
on the newer patients diagnosed with AJCC 6th edition and the
recoded 7th edition are not included in this manuscript and are
available in [21].
Specifically, good prognosis group had significantly lower
percentage of patients with COPD (p,0.05; t-tests). In lung
adenocarcinoma patients, 34.2% of patients had COPD in poor
prognosis group versus 24.2% with COPD in good prognosis
group (p,0.0001; t-tests). In squamous cell lung cancer patients,
39.9% of patients had COPD in poor prognosis groups versus
34.0% with COPD in good prognosis group (p,0.0005; t-tests).
Cancer stage was also a significant factor, and poor prognosis
group had more advanced cancer stage (p,0.0001; t-tests) in both
lung adenocarcinoma and squamous cell lung carcinima. Tumor
grade was a significant (p,0.0001; t-tests) factor in lung
adenocarcinoma, but not in squamous cell lung carcinoma.
Patient age was a significant prognostic factor in lung
adenocarcinoma and squamous cell lung carcinoma diagnosed
with all AJCC staging systems. The average patient age in lung
adenocarcinoma was 73.8 years old in poor prognosis group and
72.3 in good prognosis group (p,0.0001; t-tests); whereas the
average patient age in squamous cell lung carcinoma patients was
73.85 in poor prognosis group and 72.13 in good prognosis group
(p,0.0001; t-tests).
Patient gender was a significant prognostic factor, with more
male patients in poor prognosis group than in good prognosis
group in both adenocarcinoma and squamous cell lung carcinoma
(p,0.0001; t-tests). The percentage of male lung adenocarcinoma
patients was 39.9% in good prognosis and 56.5% in poor
prognosis; whereas in squamous cell lung carcinoma, the
percentage of male patients was 59.08% in good prognosis group
and 68.31% in poor prognosis group.
Patient race was not a significant factor in NSCLC prognosis
(Table 3). In good prognosis group of lung adenocarcinoma, there
was a higher percentage of API (5.7% vs. 4.7%) and a lower
percentage of black (5.1% vs. 6.4%) than that in poor prognosis
group, but the difference was not statistically significant. This
trend, however, was no observed in squamous cell lung carcinoma.
Prognostication Improvement with Addition of COPD in
Lung Adenocarcinoma
In a previous study, we have shown that integrating patient
information, including age, gender, race, cancer stage and tumor
grade improves the prognostication accuracy upon the cancer
staging system for both lung adenocarcinoma and squamous cell
lung carcinoma [12]. In the present study, we have established that
COPD is an independent prognostic factor for NSCLC. With the
linked SEER-Medicare database, patient treatment information,
including specific systemic therapy, could be retrieved. Hence, this
study sought to 1) investigate whether the addition of COPD into
the comprehensive model could further improve the prognostica-
tion of NSCLC; and 2) estimate the clinical outcome of 30
treatment combinations by using this comprehensive model to
guide personalized therapy.
In lung adenocarcinoma patients diagnosed with the original
AJCC 3rd Edition staging system, the addition of COPD to the
comprehensive model resulted in a significant prognostication
improvement (p,0.05; Harrell’s c-statistic) in the total patient
group receiving any treatment. Specifically, there was also
significant prognostication improvement in patients treated with
surgery alone (p,0.05; Harrell’s c-statistic) and patients without
receiving chemotherapy (p,0.05; Harrell’s c-statistic and ROC
measures; more details provided in [21]).
In lung adenocarcinoma patients diagnosed with the AJCC 6th
staging system, with the addition of COPD there was a significant
prognostication improvement in the total group of patients
receiving any treatment (p=0.0480; Harrell’s c-statistic). There
was an additional prognostication improvement in patients treated
with surgery regardless of indication of chemotherapy (p=0.0475;
ROC measure). Similar results were observed when patients were
recoded to the AJCC 7th Edition staging system. These results
indicate that the addition of COPD to the Full model could
improve the prognostic accuracy in lung adenocarcinoma patients
receiving any treatment, with the greatest prognostication
improvement in patients without receiving chemotherapy. The
detailed prognostic stratification cutoffs and model coefficients for
each staging system can be seen in Figure 2.
Prognostication Improvement with Addition of COPD in
Squamous Cell Lung Carcinoma
There was a significant prognostication improvement
(p=0.0239, Brier score) with the addition of COPD to the model
in all squamous cell lung carcinoma patients diagnosed with the
AJCC 3rd Edition staging scheme. More specifically, when any
combination of surgical or radiological treatment was considered
regardless of indication of chemotherapy, there was a significant
prognostication improvement in the total patient population
(p=0.0130; Harrell’s c-statistic). This prognostication improve-
ment was also observed in patients treated with any chemotherapy
(p=0.0244; Harrell’s c-statistic) or with a platinum-based agent
(p=0.0125; Harrell’s c-statistic). A similar prognostication im-
Predicting NSCLC Treatment Response
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provement was seen in patients treated with a platinum-based
agent, or with a platinum-based agent and a taxane and any other
surgical or radiological treatment (p,0.05; Nagelkerke’s R2 and
ROC measures). The addition of COPD to the model was able to
significantly improve prognostication in surgical patients across the
range of chemotherapy sub-groups (p,0.05; Harrell’s c-statistic).
These result indicate that the addition of COPD improves the
prognostication performance in squamous cell lung cancer overall
patient population as well as in multiple chemotherapeutic
settings.
In squamous cell lung carcinoma patients diagnosed with the
AJCC 6th staging edition, the addition of COPD into the Full
Figure 1. Kaplan-Meier analysis of patients with and without COPD among those treated with surgery alone. Log-rank tests were used
to assess the difference in survival probabilities of two groups.
doi:10.1371/journal.pone.0100994.g001
Predicting NSCLC Treatment Response
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e100994
model did not make significant difference in prognostication
performance as measured with Nagelkerke’s R2, Brier score or
ROC measures. There was, surprisingly, a significant degradation
in model performance in patients without an indication of
treatment (p=0.0089; Harrell’s c-statistic). When the patients
were recoded using the AJCC 7th Edition criteria, there was a
significant prognostication improvement in patients without
receiving chemotherapy (p=0.0489; Brier score). These results
suggest that the less pronounced prognostication improvement
with the addition of COPD in squamous cell lung cancer
diagnosed with newer AJCC staging systems might be caused by
shorter available follow-up period. The fact that the counter-
intuitive results observed in squamous cell lung cancer diagnosed
with AJCC 6th staging edition but not with the recoded 7th edition
suggests the newest staging system might improve the disease
classification. The final prognostic model for squamous cell lung
carcinoma patients for each staging system can be seen in Figure 3.
An interactive web-based prognostic tool based on the models
developed in this study is available at www.personalizedRx.org
and an example is provided in Figure 4.
Discussion
Lung cancer is a dynamic and diverse disease and associated
with numerous somatic mutations, deletion and amplification
events. The heterogeneous nature of lung cancer makes it a very
difficult disease in the clinical managements and it has remained
the leading cause of cancer-related deaths for both men and
women. Surgical resection is the major treatment option for early
stage NSCLC. However, about 35–50% of stage I NSCLC
patients will develop tumor recurrence within five years following
the surgery [2,3], and adjuvant chemotherapy of stage II and stage
III disease has resulted in very modest survival benefits [22]. It
remains a critical issue to recommend appropriate treatment
course for an individual patient based on his/her clinical,
pathological, demographic and co-morbid conditions, as well as
genetic portraits. Using large-scale patient electronic medical
records enables the development of a comprehensive prognostic
model to estimate treatment response for a particular patient. Such
model could potentially be integrated with genetic biomarkers for
treatment selection. Our previous study developed a comprehen-
sive prognostic model for NSCLC by using patient information
including age, gender, race, cancer stage, tumor grade, and
histology [12]. However, this prognostic model did not include co-
morbid conditions and particular use of chemotherapy.
Table 2. Association of each comorbid condition and NSCLC survival when the patient sample was restricted to patients receiving
surgery without radiation or chemotherapy.
Adenocarcinoma Squamous Cell
Condition Hazard Ratio p-value Hazard Ratio p-value
Congestive Heart Failure 1.37 ,0.0001* 1.27 0.0003*
Peripheral Vascular Disease 1.22 0.0020* 1.03 0.7234
Cerebrovascular Disease 1.16 0.0152* 1.06 0.3874
COPD 1.24 ,0.0001* 1.11 0.0140*
Diabetes with sequelae 1.26 0.0186* 1.06 0.5964
Chronic Renal Failure 1.18 0.4083 1.57 0.0002*
Cirrhosis 0.74 0.3000 1.95 0.0024*
Gastrointestinal Ulcers 1.33 0.0193* 1.22 0.1337
* indicates statistical significance at a P,0.05 level.
doi:10.1371/journal.pone.0100994.t002
Table 3. Comparison of patient information in good prognosis (those survived more than 5 years) and poor prognosis (those
survived less than 2 years) groups when the patient sample was restricted to patients receiving surgery without radiation or
chemotherapy.
Adenocarcinoma Squamous
Variables\Group Good Prognosis Poor Prognosis P-Value Good Prognosis Poor Prognosis P-Value
With COPD (%) 24.2% 34.2% ,0.0001* 34.0% 39.9% ,0.0001*
Cancer stage (mean) 1.17 2.03 ,0.0001* 1.26 1.91 ,0.0001*
Tumor grade (mean) 2.08 2.46 ,0.0001* 2.50 2.53 0.15*
Age (mean) 72.30 73.80 ,0.0001* 72.13 73.85 ,0.0001*
Gender (Male %) 39.90% 56.50% ,0.0001* 59.08% 68.31% ,0.0001*
Race (API %) 5.70% 4.70% 0.14 3.51% 3.54% 1
Race (Black %) 5.10% 6.40% 0.087 8.68% 8.03% 0.55
These patients were diagnosed with AJCC 3rd staging edition. * indicates statistical significance at a P,0.05 level.
doi:10.1371/journal.pone.0100994.t003
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Assessment of the effect of COPD in NSCLC prognosis is
important due to potential shared origins in the development of
lung cancer and COPD [23–25] and the role of COPD as a
common and important independent risk factor for lung cancer
[9]. It is hypothesized that inflammation may initiate or promote
tumorigenesis in the lung [23–25]. This action is thought to center
around the induction of immune dysfunction and the destruction
of the extra-cellular matrix [26]. A recent study suggested that the
Figure 2. Comprehensive prognostic model for lung adenocarcinoma. Patient survival at 60 months for the total population sample is
shown for the range of Hazard Scores (left), with the risk-groups delimited by vertical bars. Model coefficients used to determine the Hazard Score for
each patient are shown on the forest plot (right). A: AJCC 3rd Staging Edition; B: AJCC 6th Staging Edition; C: AJCC 7th Staging Edition.
doi:10.1371/journal.pone.0100994.g002
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Figure 3. Comprehensive model for squamous cell lung carcinoma. Model coefficients used to determine the Hazard Score for each patient
are shown on the forest plot (right). Patient survival at 24 months for the total population sample is shown for the range of Hazard Scores (left), with
the risk-groups delimited by vertical bars. A: AJCC 3rd Staging Edition; B: AJCC 6th Staging Edition; C: AJCC 7th Staging Edition.
doi:10.1371/journal.pone.0100994.g003
Predicting NSCLC Treatment Response
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e100994
potential role of hypoxic regions of the lung is a possible
mechanism for the association between COPD and lung cancer
[27]. Both inflammation and hypoxia contribute to the tumor
microenvironment and may impact lung cancer prognosis and
response to specific treatment. The results from this study
demonstrate that NSCLC patients with COPD had significantly
worse clinical outcome than those without COPD. In order to
account for known confounders such as treatment candidacy and
complication rate [6,28], the effect of COPD was further
examined within treatment and cancer stage sub-set. The results
show that COPD could significantly stratify patients into different
prognostic groups within each specific treatment and cancer stage,
indicating that COPD is an independent and significant prognos-
tic factor of NSCLC. The relatively stronger prognostic effect of
COPD in squamous cell lung carcinoma compared with lung
adenocarcinoma may be indicative of the role of smoking on both
survival and the presence of COPD itself, with squamous cell
carcinomas being more closely associated with smoking than
adenocarcinomas [29–31].
The overall co-morbid condition as defined with the CCI index
was also significantly associated with NSCLC disease-specific
survival in this study (results not shown). Specifically, congestive
heart failure, peripheral vascular disease, cerebrovascular disease,
diabetes with sequelae, and gastrointestinal ulcers had a significant
(p,0.05) association with disease-specific survival, respectively.
These co-morbid conditions are more likely to derive their
prognostic value from confounding or artifactual influences such
as socio-economic status or lifestyle differences, instead of
molecular mechanistic effects on lung cancer tumor progression.
Thus, their inclusion, while potentially beneficial from a statistical
standpoint, is imprudent when attempting to model factors directly
influencing lung cancer progression and patient survival [32]. In
contrast, there was no evidence found in the literature suggesting
that the trajectory or treatment of COPD will affect survival
estimation in lung cancer patients. For these reasons, COPD alone
was added to the prognostic model in lieu of co-morbid conditions.
The SEER data is composed of a geographically and
demographically diverse group of patients and thus allows for a
more accurate analysis of the prognostic effect of multiple
variables. The large size and scope of the data also allow for
assessing the accuracy of the model across a wide range of
treatments and patient profiles. This is especially relevant when
studying the effects of race or comorbidity, factors which have
previously been shown to influence survival due to differences in
treatments administered [33]. Given the assessment of disease-
specific survival stratified by treatment modality, it is highly likely
that the effect of COPD represents an additional source of risk to
the patient beyond that attributable to reduced candidacy,
complication rate, or reduced lung function after treatment. The
comprehensive model developed in this study also accounts for
recoding of cancer cases to the newest version of the 7th AJCC
staging scheme, where possible, and includes both major non-
small cell histologies. The prognostic utility of COPD is less
pronounced in the AJCC 6th Edition and recoded 7th Edition
patients compared with those diagnosed with the AJCC 3rd staging
system, possibly because the newer patient groups have both a
smaller sample-size and a shorter period of follow-up. It is likely
that important manifestations of differences in survival due to
COPD may occur beyond the three-year mark, or more recent
improvements in the clinical management of COPD cases may
alleviate some of the disparity in lung cancer survival, which is
beyond the scope of this study.
A limitation of the data is that Medicare coverage is limited to
those over the age of 65, with some exceptions, and thus the age
distribution of patients included is likely biased toward the upper
end of what would be seen in clinical practice. Additionally, the
administration of chemotherapeutics or other treatments not
covered by Medicare is not recorded in the data, although
Medicare covers a significant portion of cancer care in patients
who are eligible [34]. As the treatments administered to each
patient were non-random, it is also difficult to accurately assess the
relative benefit of each type of treatment and thus for this and
other reasons the results should not be interpreted as a measure of
comparative treatment effectiveness in a randomized clinical trial.
In addition, the absence of information on smoking status may also
limit the model, as smoking has been shown to influence NSCLC
survival independent of co-morbidities [35,36] and other clinical,
pathological, and demographic information [37]. The previous
version of the prognostic model without the inclusion of COPD
was built on SEER data, and validated with two external patient
cohorts [12]. This study extends the previous model with the
inclusion of COPD and provides survival estimates for a wide
range of treatment modalities including multiple chemotherapeu-
tic agents. While the metrics used to assess model performance
indicate that the comprehensive prognostic model presented in this
study has a high degree of internal validity, an external validation
set was not used because there were no available patient cohorts
with sufficient sample size and all the information required in this
model.
The administrative data is adequate for assessing co-morbidities
and the use of chemotherapeutics [18,38]. Our results demon-
strate that the addition of co-morbid conditions, specifically
Figure 4. An example of output from the web-based version of the comprehensive prognostic model. Given the patient information
submitted by the user (left), the web-based tool will estimate survival for each treatment category using the survival observed for patients of a
particular treatment modality and similar Hazard Score (right).
doi:10.1371/journal.pone.0100994.g004
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COPD, to a comprehensive model improves prognostication over
similar models without that information. This represents an
additional prognostication improvement over the use of cancer
stage alone, which has already been validated with statistical rigor
[12]. This comprehensive model enables refined prognosis and
estimation of clinical outcome of 30 treatment combinations in
NSCLC patients, providing a useful tool in personalized clinical
decision-making. An online tool based on this model is available at
www.personalizedRx.org, which has already been in use in clinics
at Mary Babb Randolph Cancer Center. With the advancement of
clinical genomics research [39–43], this comprehensive prognostic
model could be integrated with future genomic biomarkers to
predict NSCLC patient treatment response.
Supporting Information
Figure S1 Effect of COPD in Adenocarcinoma AJCC 3rd
Edition stage and treatment sub-groups. For each group, a
clear and significant difference between the survival curves for
patients with and without COPD can be seen, with patients
identified as having COPD experiencing significantly poorer
survival compared to those without COPD.
(PPTX)
Figure S2 Effect of COPD in Adenocarcinoma AJCC 6th
Edition stage and treatment sub-groups. For each group,
patients without COPD tend to experience longer survival when
compared to patients with COPD, although the difference is not
significant in some cases shown.
(PPTX)
Figure S3 Effect of COPD in Adenocarcinoma AJCC 7th
Edition stage and treatment sub-groups. For each group
treated without chemotherapy, a clear and significant difference
between the survival curves for patients with and without COPD
can be seen, with patients identified as having COPD experiencing
significantly poorer survival compared to those without the
disease. The difference in survival for patients treated with
systemic therapy was not significant, but trended toward patients
with COPD having poorer survival.
(PPTX)
Figure S4 Effect of COPD in Squamous Cell AJCC 3rd
Edition stage and treatment sub-groups. For each group, a
clear and significant difference between the survival curves for
patients with and without COPD can be seen, with patients
identified as having COPD experiencing significantly poorer
survival compared to those without the disease.
(PPTX)
Figure S5 Effect of COPD in Squamous Cell AJCC 6th
Edition stage and treatment sub-groups. For the group
shown, a clear and significant difference between the survival
curves for patients with and without COPD can be seen, with
patients identified as having COPD experiencing significantly
poorer survival compared to those without the disease.
(PPTX)
Figure S6 Effect of COPD in Squamous Cell AJCC 7th
Edition stage and treatment sub-groups. For each group, a
clear and significant difference between the survival curves for
patients with and without COPD can be seen, with patients
identified as having COPD experiencing significantly poorer
survival compared to those without the disease.
(PPTX)
Figure S7 Improvement in the Full model using COPD
over Stage Alone. For each Kaplan-Meier plot, the three pairs
of lines represent the High, Intermediate, and Low-Risk groups
defined for each of the two models shown. The model using only
AJCC Stage is shown in orange, while the Full model with COPD
status added is shown in blue. For each plot shown, the Full model
with COPD status was able to produce a Low-Risk group with
better survival and a High-Risk group with poorer survival, with
most cases being significant (p,0.05).
(PPTX)
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